Clinical trials: Mask
Dry Eye
ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease
- Trial name
- OASIS-1 (NCT04899518)
- Testing
- ALY688 Ophthalmic Solution
- Where
- United States
- Volunteers
- 922 people
- Sponsor
- Allysta Pharmaceutical
Diabetic Macular Edema (DME)
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
The purpose of this study is to learn about the effects of BGE-102 on change in vision in participants with center-involved diabetic macular edema (CI-DME).
- Trial name
- QUELL-DME (NCT07812090)
- Testing
- Oral BGE-102, Anti-VEGF
- Where
- 16 sites in United States
- Volunteers
- 180 people
- Sponsor
- BioAge Labs, Inc.
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work.
- Trial name
- NCT06280235
- Testing
- BI 1569912
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular…
- Trial name
- REVEAL (NCT00989989)
- Testing
- Ranibizumab, Laser photocoagulation
- Where
- 35 sites in China, Hong Kong and 4 more
- Volunteers
- 396 people
- Sponsor
- Novartis
Dry Eye Disease
Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.
The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.
- Trial name
- NCT05695781
- Testing
- BRM421 Ophthalmic Solution, Vehicle
- Where
- United States
- Volunteers
- 740 people
- Sponsor
- BRIM Biotechnology Inc.
Dry Eye
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-1 (NCT03334539)
- Testing
- HL036 ophthalmic solution
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- HanAll BioPharma Co., Ltd.
Macular Degeneration, Age-related, Geographic Atrophy
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan.
- Trial name
- VERDANT (NCT06722157)
- Testing
- BI 771716, Pegcetacoplan
- Where
- 46 sites in United States
- Volunteers
- 202 people
- Sponsor
- Boehringer Ingelheim
Open Angle Glaucoma, Ocular Hypertension
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used…
- Trial name
- NCT01342081
- Testing
- DE-111 ophthalmic solution, Tafluprost ophthalmic solution 0.0015%, Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%
- Where
- Japan
- Volunteers
- 489 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Primary Open-angle Glaucoma (POAG), Ocular Hypertension
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Safety and tolerability of three different concentrations (0.1%, 03%, 0.6%) of the investigational SHP639 eye drops will be evaluated in participants with high eye pressure or primary open-angle glaucoma.
- Trial name
- NCT03131167
- Testing
- SHP639 (n=60)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Shire
Thyroid Eye Disease
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
- Trial name
- THRIVE-2 (NCT06021054)
- Testing
- Veligrotug
- Where
- 57 sites in United States, Australia and 7 more
- Volunteers
- 188 people
- Sponsor
- Viridian Therapeutics, Inc.
Osteoarthritis
Efficacy and Safety of Intraarticular Injections of Hyalgan in the Treatment of Osteoarthritis of the Knee
Evaluate the efficacy and safety of Hyalgan, at a dose of 20mg/2ml administered as 5 intraarticular injections at weekly intervals, for the sustained relief of pain and amelioration of joint dysfunction in patients of OA of the…
- Trial name
- NCT01319461
- Testing
- Hyalgan, sterile normal saline
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Med Pharma Co., Ltd.
Branch Retinal Vein Occlusion
Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
This is a phase III, double-masked, randomized, active-controlled, parallel-group, 52-week study to assess the efficacy and safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) compared to laser treatment in…
- Trial name
- VIBRANT (NCT01521559)
- Testing
- Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
- Where
- 56 sites in United States, Canada and 1 more
- Volunteers
- 183 people
- Sponsor
- Regeneron Pharmaceuticals
Obstructive Sleep Apnea
A Development Study to Evaluate a Nasal Mask for the Treatment of Obstructive Sleep Apnea
This investigation is designed to evaluate the comfort, ease of use and performance of a trial nasal mask for the treatment of Obstructive Sleep Apnea (OSA) in the home environment.
- Trial name
- NCT03124069
- Testing
- F&P Saturn
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Fisher and Paykel Healthcare
Cataract Surgery
Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery
The purpose of this study is to evaluate superior efficacy of DE-108 ophthalmic solution to that of Levofloxacin 0.5% ophthalmic solution as well as safety of the former used for perioperative bacteria eradication in patients who…
- Trial name
- NCT02573610
- Testing
- DE-108, Levofloxacin 0.5%
- Where
- 6 sites in South Korea
- Volunteers
- 576 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma, Ocular Hypertension
Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US
Compare the IOP lowering properties of latanoprost, travoprost and bimatoprost
- Trial name
- XLT (NCT00847483)
- Testing
- latanoprost 0.005% ophthalmic solution, Travoprost 004% sterile ophthalmic solution, Bimatoprost .03% sterile ophthalmic solution
- Where
- 40 sites in United States
- Volunteers
- 375 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Dry Eye
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
- Trial name
- NCT06296966
- Testing
- VSJ-110
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanda Pharmaceuticals
Macular Edema
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic macular edema (CI-DME) to take…
- Trial name
- NCT06962839
- Testing
- BI 1815368
- Where
- 97 sites in United States, China and 7 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema…
- Trial name
- BRUNELLO (NCT06571045)
- Testing
- Ranibizumab, Remigromig
- Where
- 183 sites in United States, Argentina and 18 more
- Volunteers
- 984 people
- Sponsor
- EyeBiotech Ltd.
Dry Eye Syndrome
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT02974907
- Testing
- RGN-259
- Where
- 10 sites in United States
- Volunteers
- 601 people
- Sponsor
- ReGenTree, LLC
Dry Age-related Macular Degeneration
Microcurrent Stimulation for Dry Age-related Macular Degeneration
Evaluate the safety and efficacy of microcurrent stimulation therapy for patients with dry age-related macular degeneration.
- Trial name
- i-SIGHT (NCT04511936)
- Testing
- i-Lumen AMD
- Sponsor
- i-Lumen Scientific, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.